Financial Results - Standalone (Q1 FY2026)

Income Statement Highlights (₹ millions):

  • Revenue from operations: ₹8,018.77 (Q1 FY2025: ₹8,768.21)
  • Sale of products: ₹7,788.83
  • Other operating revenue: ₹229.94
  • Other income: ₹137.84
  • Total income: ₹8,156.61
  • Total expenses: ₹7,190.97
  • Cost of materials consumed: ₹3,771.24
  • Employee benefits expense: ₹1,131.76
  • Finance costs: ₹96.14
  • Depreciation and amortization: ₹390.61
  • Other expenses: ₹2,034.87
  • Profit before exceptional items and tax: ₹965.64 (Q1 FY2025: ₹1,320.84)
  • Exceptional items: None (Q1 FY2025: None)
  • Profit before tax: ₹965.64
  • Total tax expense: ₹248.18
  • Current tax: ₹265.60
  • Deferred tax: ₹(17.42)
  • Profit for the period: ₹717.46 (Q1 FY2025: ₹989.87)
  • Total comprehensive income: ₹956.50 (Q1 FY2025: ₹754.89)

Key Metrics:

  • Basic EPS: ₹2.90 (Q1 FY2025: ₹4.04)
  • Diluted EPS: ₹2.84 (Q1 FY2025: ₹4.04)
  • Paid-up equity share capital: ₹247.80 million

Financial Results - Consolidated (Q1 FY2026)

Income Statement Highlights (₹ millions):

  • Total income: ₹14,790.41
  • Total expenses: ₹12,383.70
  • Profit before exceptional items and tax: ₹2,404.04
  • Exceptional items: None
  • Profit before tax: ₹2,404.04
  • Total tax expense: ₹604.41
  • Profit for the period: ₹1,799.63
  • Total comprehensive income: ₹2,100.24

Key Metrics:

  • Basic EPS: ₹7.26
  • Diluted EPS: ₹7.11
  • Paid-up equity share capital: ₹247.80 million

Operational and Corporate Updates

Business Segment:

The Company operates in one reportable business segment of Pharmaceutical products including ingredients and intermediaries.

Capital Raising Activity:

During the quarter and year ended March 31, 2026, the Company allotted 5,128,205 equity shares of ₹1 each fully paid up to non-promoter category members on a preferential basis.

Warrant Issuance:

The Board approved issuance of 25,000,000 warrants convertible into equity shares on preferential basis to Promoter and Non-Promoter categories for up to ₹14,625 million at ₹585 per warrant. Shareholders approved the issuance on January 22, 2026. The Company received ₹3,656.25 million on February 23, 2026 towards minimum 25% of the total consideration.

Regulatory Matter:

The Gagillapur facility received a USFDA warning letter in February 2025 following an August-September 2024 inspection. The Company has implemented remedial measures including engaging independent consultants, enhancing procedures, and implementing corrective actions.

Exceptional Items:

For previous periods, exceptional items included transaction costs of ₹121.60 million related to the acquisition of Senn Chemicals AG (Q1 FY2025 and FY2026).

Subsidiary Information:

The consolidated results include subsidiaries: Granules Pharmaceuticals Inc., Granules Consumer Health LLC, Granules Life Sciences Private Limited, Granules CZRO Private Limited, Ascelis Peptides Private Limited, Senn Chemicals AG (w.e.f. April 10, 2025), Granules Pharmaceuticals GMBH (w.e.f November 20, 2025), and Granules Pharmaceuticals Canada, Inc. (w.e.f November 26, 2025).

Auditor Review

S.R. Batliboi & Associates LLP conducted limited review of both standalone and consolidated financial results and issued unmodified review conclusions.

Meeting Details

The Board meeting commenced at 10:15 AM and concluded at 12:00 PM on July 21, 2026.